Management of bone loss in men with prostate cancer

Journal of Urology

Volumn 170, Issue 6 II, 2003, Pages

  Higano, Celestia S ^a   Oh, William K ^b   Nelson, Joel B ^b   Roach III, Mack ^b   Higano, Celestia ^b   Smith, Matthew R ^b   Nanus, David ^b   Kantoff, Philip W ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

Bisphosphonates; Bone mineral density; Osteoporosis; Prostatic neoplasms

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DIETHYLSTILBESTROL; PAMIDRONIC ACID; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RISEDRONIC ACID; SALCATONIN; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE METASTASIS; CANCER HORMONE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HUMAN; HYPOGONADISM; INCIDENCE; MALE; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; VITAMIN D DEFICIENCY;

EID: 0242523963     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000097351.48848.1f     Document Type: Conference Paper

References (53)

1. Orwoll, E. S. and Klein, R. F.: Osteoporosis in men. Endocrine Rev, 16: 87, 1995
2. Orwoll, E. S., Oviatt, S. K., McClung, M. R., Deftos, L. J. and Sexton, G.: The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med, 112: 29, 1990
3. Mazess, R. B., Barden, H. S., Drinka, P. J., Bauwens, S. F., Orwoll, E. S. and Bell, N. H.: Influence of age and body weight on spine and femur bone mineral density in U. S. white men. J Bone Miner Res, 5: 645, 1990
4. Tobin, J. D., Fox, K. M. and Cejku, M. L.: Bone density changes in normal men: a 4-19 year longitudinal study. J Bone Miner Res, suppl., 8: S142, 1993
5. Mann, T., Oviatt, S. K., Wilson, D., Nelson, D. and Orwoll, E. S.: Vertebral deformity in men. J Bone Miner Res, 7: 1259, 1992
6. Melton, L. J., III: Epidemiology of osteoporosis. Trends Endocrinol Metab, 3: 224, 1992
7. Vermeulen, A.: Clinical review 24: androgens in the aging male. J Clin Endocrinol Metab, 73: 221, 1991
8. Colvard, D. S., Eriksen, E. F., Keeting, P. E., Wilson, E. M., Lubahn, D. B., French, F. S. et al: Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA, 86: 854, 1989
9. Slemenda, C. W., Longcope, C., Zhou, L., Hui, S. L., Peacock, M. and Johnston, C. C.: Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest, 100: 1755, 1997
10. 6-GnRH). J Clin Endocrinol Metab, 76: 288, 1993
11. Melton, L. J., III and Riggs, B. L.: Epidemiology of age-related fractures. In: The Osteoporotic Syndrome. Edited by L. V. Avioli. New York: Grune & Stratton, pp. 45-72, 1983
12. Heyse, S. P.: Epidemiology of hip fractures in the elderly: a cross-national analysis of mortality rates for femoral neck fractures. Osteoporos Int, suppl., 3: S16, 1993
13. Seeman, E., Melton, L. J., III, O'Fallon, W. M. and Riggs, B. L.: Risk factors for spinal osteoporosis in men. Am J Med, 75: 977, 1983
14. Selby, P. L., Davies, M. and Adams, J. E.: Do men and women fracture bones at similar bone densities? Osteoporos Int, 11: 153, 2000
15. Kanis, J. A.: Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 359: 1929, 2002
16. Melton, L. J., III: The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int, 69: 179, 2001
17. Faulkner, K. G. and Orwoll, E.: Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom, 5: 87, 2002
18. Adler, R. A., Funkhouser, H. L. and Holt, C. M.: Utility of heel ultrasound bone density in men. J Clin Densitom, 4: 225, 2001
19. Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J. et al: Alendronate for the treatment of osteoporosis in men. N Engl J Med, 343: 604, 2000
20. Greenspan, S., Field-Munves, E., Tonino, R., Smith, M., Petruschke, R., Wang, L. et al: Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc, 77: 1044, 2002
21. Schnitzer, T., Bone, H. G., Crepaldi, G., Adami, S., McClung, M., Kiel, D. et al: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging, 12: 1, 2000
22. Greenspan, S. L., Bone, G., III, Schnitzer, T. J., Watts, N. B., Adami, S., Foldes, A. J. et al: Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res, 17: 1988, 2002
23. Trovas, G. P., Lyritis, G. P., Galanos, A., Raptou, P. and Constantelou, E.: A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res, 17: 521, 2002
24. Stepan, J. J., Lachman, M., Zverina, J., Pacovsky, V. and Baylink, D. J.: Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab, 69: 523, 1989
25. Eastell, R., Devogelaer, J. P., Peel, N. F., Chines, A. A., Bax, D. E., Sacco-Gibson, N. et al: Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int, 11: 331, 2000
26. Sambrook, P. and Lane, N. E.: Corticosteroid osteoporosis. Best Pract Res Clin Rheumatol, 15: 401, 2001
27. Reid, D. M., Adami, S., Devogelaer, J. P. and Chines, A. A.: Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int, 69: 242, 2001
28. Lau, E. M., Woo, J., Chan, Y. H. and Li, M.: Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone, 29: 506, 2001
29. Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J. and Blackman, M. R.: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab, 86: 724, 2001
30. Smith, M. R., McGovern, F. J., Fallon, M. A., Schoenfeld, D., Kantoff, P. W. and Finkelstein, J. S.: Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer, 91: 2238, 2001
31. Higano, C., Stephens, C., Nelson, P. et al: Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS). Proc Am Soc Clin Oncol, 18: 314a, 1999
32. Wei, J. T., Gross, M., Jaffe, C. A., Gravlin, K., Lahaie, M., Faerber, G. J. et al: Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology, 54: 607, 1999
33. Daniell, H. W.: Osteoporosis after orchiectomy for prostate cancer. J Urol, 157: 439, 1997
34. Daniell, H. W., Dunn, S. R., Ferguson, D. W., Lomas, G., Niazi, Z. and Stratte, P. T.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol, 163: 181, 2000
35. Diamond, T., Campbell, J., Bryant, C. and Lynch, W.: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer, 83: 1561, 1998
36. Kiratli, B. J., Srinivas, S., Perkash, I. and Terris, M. K.: Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology, 57: 127, 2001
37. Diamond, T. H., Winters, J., Smith, A., De Souza, P., Kersley, J. H., Lynch, W. J. et al: The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer, 92: 1444, 2001
38. Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A. et al: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 345: 948, 2001
39. Smith, M. R., Shasha, D., Mansour, R. et al: Zoledronic acid increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Presented at 3rd North American Symposium on Skeletal Complications of Malignancy, National Institute of Health, Bethesda, Maryland, April 25-27, 2002
40. Hatano, T., Oishi, Y., Furuta, A., Iwamuro, S. and Tashiro, K.: Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int, 86: 449, 2000
41. Pound, C. R. and Partin, A. W.: What does prostate-specific antigen recurrence mean? Curr Urol Rep, 1: 28, 2000
42. Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D. and Walsh, P. C.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
43. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol, 79: 235, 1997
44. Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G. et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med, 337: 295, 1997
45. Moul, J. W.: Prostate specific antigen only progression of prostate cancer. J Urol, 163: 1632, 2000
46. Labrie, F.: Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate, 43: 215, 2000
47. Eriksson, S., Eriksson, A., Stege, R. and Carlstrom, K.: Bone mineral density in patients with prostatic cancer treated with orchiectomy and with estrogens. Calcif Tissue Int, 57: 97, 1995
48. Atala, A., Amin, M. and Harty, J. I.: Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. Urology, 39: 108, 1992
49. Gerber, G. S., Zagaja, G. P., Ray, P. S. and Rukstalis, D. B.: Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology, 55: 97, 2000
50. Spetz, A. C., Hammar, M., Lindberg, B., Spangberg, A. and Varenhorst, E.: Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol, 166: 517, 2001
51. Miller, J. I. and Ahmann, F. R.: Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer. Urology, 40: 499, 1992
52. Dawson-Hughes, B., Harris, S. S., Krall, E. A. and Dallal, G. E.: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med, 337: 670, 1997
53. Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L. et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate cancer. J Natl Cancer Inst, 94: 1458, 2002